Drug Profile
Metformin controlled-release - TWi Pharmaceuticals
Latest Information Update: 31 Aug 2023
Price :
$50
*
At a glance
- Originator TWi Pharmaceuticals
- Class Antihyperglycaemics; Biguanides; Eye disorder therapies; Small molecules
- Mechanism of Action AMP activated protein kinase stimulants; Gluconeogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 22 Aug 2023 Discontinued - Preclinical for Type 2 diabetes mellitus in Taiwan (PO) (TWi Pharmaceuticals pipeline, August 2023)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in Taiwan (PO, Controlled release)
- 16 Jul 2013 Preclinical trials in Type-2 diabetes mellitus in Taiwan (PO)